• June 3-6, 2024
  • San Diego Convention Center, California


Thomas Miller

Thomas Miller, PhD, MBA

Global Head, Acute, Chronic & Pediatric Disease Nucleus
Dr. Thomas F. Miller is Vice President & Global Head, Acute, Chronic and Pediatric Disease Nucleus in Bayer’s Pharmaceutical Division, a role he assumed earlier this year. He joined Bayer in 2017 to create and effectuate their Pediatric Clinical Development function. In total, Dr. Miller’s career in the life science industry spans more than 28 years, with a primary focus on the development of therapeutics, medical devices and combination products for pediatric and rare disease patients. Prior to joining Bayer, Dr. Miller served in the capacity of Chief Executive Officer of Therabron Therapeutics, Inc. with oversight of all operational functions for the company (R&D, manufacturing, quality, regulatory affairs, etc.). While at Therabron, he oversaw their clinical program through Phase 2 completion for their lead molecule (orphan pediatric disease) and secured both the Rare Pediatric Disease and Fast Track designations for this program. Prior to Therabron, Dr. Miller served in the capacity of Chief Operating Officer of Discovery Laboratories, Inc. During his tenure, the company successfully secured marketing authorization for their first approved therapeutic, successfully registered their first medical device and advanced multiple rare disease pipeline programs into the clinic. Earlier, Dr. Miller served in operational roles of increasing responsibility at Pfizer, Novartis, BASF Pharma, and Johnson & Johnson. He received his doctorate from the Temple University School of Medicine, his MBA from Fairleigh Dickenson University and his bachelor’s degree from Fairfield University. Dr. Miller has authored several peer-reviewed publications, given numerous presentations at scientific symposia and is an inventor with an issued and licensed patent in the field of pediatric respiratory drug delivery.
Speaking In


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.